Targeted therapy in gastric cancer

APMIS

Volumn 123, Issue 5, 2015, Pages 365-372

  Thiel, Alexandra ^a,b   Ristimäki, Ari ^a,b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Gastric cancer; HER 2; Targeted therapy; Trastuzumab; VEGFR 2

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MAMMALIAN TARGET OF RAPAMYCIN; RAMUCIRUMAB; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; TRASTUZUMAB; VASCULOTROPIN RECEPTOR 2; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; HGF PROTEIN, HUMAN; MONOCLONAL ANTIBODY; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2, HUMAN;

CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; DRUG TARGETING; GENE AMPLIFICATION; HUMAN; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; STOMACH CANCER; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES; STOMACH NEOPLASMS; TRENDS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HEPATOCYTE GROWTH FACTOR; HUMANS; MOLECULAR TARGETED THERAPY; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84928295481     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/apm.12359     Document Type: Review

References (56)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO: Classification of Tumours of the Digestive System, 4th edn. Geneva, Switzerland: IARC Press, 2010.
3. Duraes C, Almeida GM, Seruca R, Oliveira C, Carneiro F. Biomarkers for gastric cancer: prognostic, predictive or targets of therapy? Virchows Arch 2014;464:367-78.
4. GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group, Oba K, Paoletti X, Bang YJ, Bleiberg H, Burzykowski T, Fuse N, et al. Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis. Eur J Cancer 2013; 49:1565-77.
5. Cervantes A, Roda D, Tarazona N, Rosello S, Perez-Fidalgo JA. Current questions for the treatment of advanced gastric cancer. Cancer Treat Rev 2013;39:60-7.
6. Lurje G, Lenz HJ. EGFR Signaling and Drug Discovery. Oncology 2009;77:400-10.
7. Jones KL, Buzdar AU. Evolving novel anti-HER2 strategies. Lancet Oncol 2009;10:1179-87.
8. Resende C, Ristimaki A, Machado JC. Genetic and epigenetic alteration in gastric carcinogenesis. Helicobacter 2010;15(Suppl 1):34-9.
9. Ruschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, Penault-Llorca F, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol 2012;25:637-50.
10. Jorgensen JT, Hersom M. HER2 as a prognostic marker in gastric cancer - A systematic analysis of data from the literature. J Cancer 2012;3:137-44.
11. Kushima R, Kuwata T, Yao T, Kuriki H, Hashizume K, Masuda S, et al. Interpretation of HER2 tests in gastric cancer: confirmation of interobserver differences and validation of a QA/QC educational program. Virchows Arch 2014;464:539-45.
12. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-97.
13. Gu J, Zheng L, Wang Y, Zhu M, Wang Q, Li X. Prognostic significance of HER2 expression based on trastuzumab for gastric cancer (ToGA) criteria in gastric cancer: an updated meta-analysis. Tumour Biol 2014;35:5315-21.
14. Hoffmann-La Roche. A study of capecitabine (xeloda) in combination with trastuzumab (herceptin) and oxaliplatine in patients with resectable gastric cancer. In: ClincalTrials.gov. Bethesda, MD: National library of medicine (US). Available at: http://clinicaltrials.gov/show/NCT01130337. NLM identifier: NCT01130337. (Accessed 22 May 2014).
15. Hoffmann-La Roche. A study of the combination of oxaliplatin, capecitabine and herceptin (trastuzumab) and chemoradiotherapy in the adjuvant setting in operated patients with HER2 + gastric or gastro-esophageal junction cancer (TOXAG study). In: ClincalTrials.gov. Bethesda, MD: National library of medicine (US). Available at: http://clinicaltrials.gov/show/NCT01748773. NLM identifier: NCT01748773. (Accessed 22 May 2014).
16. Iqbal S, Goldman B, Fenoglio-Preiser CM, Lenz HJ, Zhang W, Danenberg KD, et al. Southwest oncology group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer. Ann Oncol 2011;22:2610-5.
17. Hecht J, Bang Y, Qin S, Chung H, Xu J, Park J, et al. Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): the TRIO-013/LOGiCTrial. J Clin Oncol 2013; 31(Suppl 15):LBA4001. Abstract
18. Bang Y. A randomized, open-label, phase III study of lapatinib in combination with paclitaxel versus weekly paclitaxel alone in the second-line treatment of HER2 amplified advanced gastric cancer (AGC) in asian population: tytan study. J Clin Oncol 2012; 30(Suppl 4):11. Abstract
19. Hoffmann-La Roche. A study of perjeta (pertuzumab) in combination with herceptin (trastuzumab) and chemotherapy in patients with HER2 -positive metastatic gastroesophageal junction or gastric cancer. In: ClincalTrials.gov. Bethesda, MD: National library of medicine (US). Available at: http://clinicaltrials.gov/show/NCT01774786. NLM identifier: NCT01774786. (Accessed 22 May 2014).
20. Jorgensen JT. Role of human epidermal growth factor receptor 2 in gastric cancer: biological and pharmacological aspects. World J Gastroenterol 2014;20:4526-35.
21. Won E, Janjigian YJ, Ilson DH. HER2 directed therapy for Gastric/Esophageal cancers. Curr Treat Options Oncol 2014;15:395-404.
22. Kim MA, Lee HS, Lee HE, Jeon YK, Yang HK, Kim WH. EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology 2008;52:738-46.
23. Begnami MD, Fukuda E, Fregnani JH, Nonogaki S, Montagnini AL, da Costa WL, et al. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. J Clin Oncol 2011;29:3030-6.
24. Terashima M, Kitada K, Ochiai A, Ichikawa W, Kurahashi I, Sakuramoto S, et al. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res 2012;18:5992-6000.
25. Chen C, Yang JM, Hu TT, Xu TJ, Yan G, Hu SL, et al. Prognostic role of human epidermal growth factor receptor in gastric cancer: a systematic review and meta-analysis. Arch Med Res 2013a;44:380-9.
26. Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 2013;14:490-9.
27. Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AF, Okines C, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol 2013;14:481-9.
28. Rojo F, Tabernero J, Albanell J, Van Cutsem E, Ohtsu A, Doi T, et al. Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J Clin Oncol 2006;24:4309-16.
29. Rodriguez CP, Adelstein DJ, Rice TW, Rybicki LA, Videtic GM, Saxton JP, et al. A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer. J Thorac Oncol 2010;5:229-35.
30. Dragovich T, McCoy S, Fenoglio-Preiser CM, Wang J, Benedetti JK, Baker AF, et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006;24:4922-7.
31. Wainberg ZA, Lin LS, DiCarlo B, Dao KM, Patel R, Park DJ, et al. Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction. Br J Cancer 2011;105:760-5.
32. Jung YD, Mansfield PF, Akagi M, Takeda A, Liu W, Bucana CD, et al. Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur J Cancer 2002;38:1133-40.
33. Chen J, Zhou SJ, Zhang Y, Zhang GQ, Zha TZ, Feng YZ, et al. Clinicopathological and prognostic significance of galectin-1 and vascular endothelial growth factor expression in gastric cancer. World J Gastroenterol 2013b;19:2073-9.
34. Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010;28:780-7.
35. Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014;383:31-9.
36. Wilke H, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, et al. RAINBOW: a global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitacel in the treamtent of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum-and fluoropyrymidine-containing combination therapy rainbow IMCL CP12-0922 (I4T-IE-JVBE). J Clin Oncol 2014; 32(Suppl 3):LBA7. Abstract
37. Eli Lilly and Company. A study of ramucirumab in patients with gastric, esophageal and gastroesophageal cancer. In: ClincalTrials.gov. Bethesda, MD: National library of medicine (US). Available at: http://clinicaltrials.gov/show/NCT01246960. NLM identifier: NCT01246960. (Accessed 26 May 2014).
38. Li J, Qin S, Xu J, Guo W, Xiong J, Bai Y, et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol 2013;31:3219-25.
39. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011;29:3968-76.
40. Van Cutsem E, de Haas S, Kang YK, Ohtsu A, Tebbutt NC, Ming XJ, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol 2012;30:2119-27.
41. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004;4:335-48.
42. Cejka D, Preusser M, Woehrer A, Sieghart W, Strommer S, Werzowa J, et al. Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo. Cancer Biol Ther 2008;7:1377-85.
43. Martin ME, Perez MI, Redondo C, Alvarez MI, Salinas M, Fando JL. 4E binding protein 1 expression is inversely correlated to the progression of gastrointestinal cancers. Int J Biochem Cell Biol 2000;32:633-42.
44. Okamoto I, Doi T, Ohtsu A, Miyazaki M, Tsuya A, Kurei K, et al. Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumors. Jpn J Clin Oncol 2010;40:17-23.
45. Doi T, Muro K, Boku N, Yamada Y, Nishina T, Takiuchi H, et al. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol 2010;28:1904-10.
46. Ohtsu A, Ajani JA, Bai YX, Bang YJ, Chung HC, Pan HM, et al. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol 2013;31:3935-43.
47. Al-Batran SE. A randomized, double blind study evaluationg paclitaxel with and without RAD001 in patients with gastric adenocarcinoma after prior chemotherapy (AIO-STO-0111). In: ClincalTrials.gov. Bethesda, MD: National library of medicine (US). Available at: http://clinicaltrials.gov/show/NCT01248403. NLM identifier: NCT01248403. (Accessed 26 May 2014).
48. Scagliotti GV, Novello S, von Pawel J. The emerging role of MET/HGF inhibitors in oncology. Cancer Treat Rev 2013;39:793-801.
49. Peters S, Adjei AA. MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol 2012;9:314-26.
50. Yu S, Yu Y, Zhao N, Cui J, Li W, Liu T. C-met as a prognostic marker in gastric cancer: a systematic review and meta-analysis. PLoS ONE 2013;8:e79137.
51. Lennerz JK, Kwak EL, Ackerman A, Michael M, Fox SB, Bergethon K, et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 2011;29:4803-10.
52. Unicancer. Phase 2 study assessing efficacy and safety of crizotinib in patients harboring an alteration on ALK, MET or ROS1 (AcSé). In: ClincalTrials.gov. Bethesda, MD: National library of medicine (US). Available at: http://clinicaltrials.gov/show/NCT02034981. NLM identifier: NCT02034981. (Accessed 28 May 2014).
53. Oliner KS, Tang R, Aderson A, Lan Y, Iveson T, Donehower R.C., et al. Evaluation of MET pathway biomarkers in a phase II study of rilotumumab (R, AMG 102) or placebo (P) in combination with epirubicin, cisplatin, and capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer. J Clin Oncol 2012; 30(Suppl 15):4005. Abstract
54. Cunningham D, Al-Batran SE, Davidenko I, Ilson DH, Murad AM, Tebbutt NC, et al. RILOMET-1: an international phase III multicenter, randomized, double-blind, placebo-controlled trial of rilotumumab plus epirubicin, cisplatin, and capecitabine (ECX) as first-line therapy in patients with advanced MET-postive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. J Clin Oncol 2013a;31(Suppl 15):TPS4153. Abstract
55. Amgen. A phase 3 study of rilotumumab (AMG 102) with cisplation and capecitabine (CX) as first-line therapy in gastric cancer (RILOMET-2). In: ClincalTrials.gov. Bethesda, MD: National library of medicine (US). Available at: http://clinicaltrials.gov/show/NCT02137343. NLM identifier: NCT02137343. (Accessed 28 May 2014).
56. Cunningham D, Bang YJ, Tabernero J, Shah MA, Lordick F, Hack SP. MetGastric: a randomized phase III study of onartuzumab (MetMAb) in combination with mFOLFOX6 in patients with metastatic HER2-negative and MET-positive adenocarcinoma of the stomach or gastroesophageal juntion. J Clin Oncol 2013b; 31(Suppl 15):TPS4155. Abstract